On this page
Beckwith-Wiedemann syndrome
This condition typically presents in infancy with features including larger-than-average birth size, asymmetric body growth, and distinctive physical characteristics. Early diagnosis and monitoring are important because affected children have an increased risk of developing certain cancers during childhood.
Overview
Beckwith-Wiedemann syndrome is an overgrowth disorder that affects approximately 1 in 10,000 to 13,000 births. Disrupted regulation of growth-controlling genes causes accelerated development both before and after birth [PMID:28151508]. The clinical presentation varies considerably across affected individuals, from subtle indicators to more obvious features.
Whilst some children experience few medical complications, others need continuing surveillance and intervention. Multiple organ systems can be involved, and certain children face heightened cancer risk during their early years [PMID:29386252]. Overgrowth tendencies generally diminish with advancing age, and most affected people go on to live healthy lives when appropriate medical oversight is in place.
Symptoms & clinical features
Clinical features of Beckwith-Wiedemann syndrome vary considerably, with no single characteristic present in all affected individuals. Macroglossia, an enlarged tongue, commonly occurs and may cause feeding difficulties in infancy or affect speech development. Many newborns present with larger-than-expected birth weight and length, and abdominal wall defects such as umbilical hernia or omphalocele occur in a substantial proportion of cases.
Haemihyperplasia - asymmetric overgrowth affecting one side of the body or specific body parts - develops in some children. Distinctive facial features may include prominent eyes, creases in the earlobes, and a flattened nasal bridge. Newborns sometimes experience hypoglycaemia (low blood sugar) in the first days of life, requiring careful monitoring. Some affected individuals develop kidney abnormalities, ranging from mild structural differences to more significant malformations requiring intervention.
Video: Genetics 101
Affected organs
Beckwith-Wiedemann syndrome primarily affects systems involved in growth regulation. The tongue often shows notable enlargement, potentially impacting feeding, breathing, and speech. The abdominal organs, particularly the liver, spleen, and kidneys, may be larger than typical for age. Kidney involvement ranges from mild enlargement to structural abnormalities such as cysts or duplicated collecting systems.
The pancreas can be affected, with some children experiencing transient hyperinsulinism causing low blood sugar in the newborn period. When haemihyperplasia is present, the skeletal and muscular systems show asymmetric growth, which may require orthopaedic monitoring. The increased tumour risk particularly affects organs where embryonal cancers arise, including the kidneys (Wilms tumour) and liver (hepatoblastoma) [PMID:29386252].
Risks & severity
The severity of Beckwith-Wiedemann syndrome spans a broad spectrum. Some individuals have mild features requiring minimal intervention, whilst others face significant medical challenges during childhood. The most serious concern is the elevated risk of embryonal tumours, which affects a small proportion of children with the condition. This tumour risk is highest during early childhood and decreases substantially after age eight [PMID:28151508].
Wilms tumour (a kidney cancer) and hepatoblastoma (a liver tumour) are the most commonly associated cancers, though other tumour types occur less frequently. Children with haemihyperplasia or certain genetic subtypes face higher tumour risks. Newborn complications, particularly hypoglycaemia and difficulties related to abdominal wall defects or macroglossia, typically resolve with appropriate management. Long-term outlook is generally favourable with proper surveillance, as most affected individuals reach adulthood without major health limitations.
Genetic causes
Beckwith-Wiedemann syndrome results from disrupted function of growth-regulating genes located in a specific region on chromosome 11 (11p15.5). Multiple genes in this chromosomal area control development during the foetal period and early childhood. Their expression normally follows a genomic imprinting pattern, meaning certain genes are only active when inherited from a particular parent.
One key gene in this region is CDKN1C, which normally acts to restrain cell growth and division [PMID:8755921]. The encoded protein operates as a cyclin-dependent kinase inhibitor, controlling progression through the cell cycle and helping maintain appropriate growth rates. Pathogenic variants in CDKN1C account for a minority of Beckwith-Wiedemann syndrome cases. More commonly, the condition arises from epigenetic changes affecting how multiple genes in the 11p15.5 region are expressed, rather than from alterations in the DNA sequence itself. These epigenetic mechanisms can disrupt the normal balance between growth-promoting and growth-restraining signals.
- CDKN1C cyclin dependent kinase inhibitor 1C
Inheritance pattern
Beckwith-Wiedemann syndrome follows an autosomal dominant inheritance pattern when caused by pathogenic variants in CDKN1C, meaning a single altered copy of the gene is sufficient to cause the condition. However, the inheritance picture is complex because most cases result from epigenetic changes that typically occur spontaneously rather than being inherited from a parent.
When a CDKN1C variant is the cause, there is up to a 50% chance of passing the condition to each child, though this depends on which parent carries the alteration - variants are only disease-causing when inherited from the mother due to genomic imprinting. Most individuals with Beckwith-Wiedemann syndrome represent the first affected person in their family. Families with a confirmed genetic cause benefit from genetic counselling to understand recurrence risks for future pregnancies and testing options for relatives.
Each child has a 50% chance of inheriting the pathogenic variant, regardless of sex.
Diagnosis & testing
Diagnosis of Beckwith-Wiedemann syndrome typically begins with clinical recognition of characteristic features, particularly when multiple signs are present. Confirmation requires specialised genetic testing, which may include analysis of the 11p15.5 chromosomal region for epigenetic changes, testing for uniparental disomy, and sequencing of CDKN1C. Because multiple genetic mechanisms can cause the condition, comprehensive testing approaches are often necessary.
Referral to clinical genetics services through the NHS Genomic Medicine Service enables access to appropriate testing and expert interpretation. Genetic counsellors help families understand test results and their implications. For pregnancies where a parent carries a known CDKN1C variant, prenatal testing options exist. Healthcare professionals may refer children with suggestive features for formal genetics evaluation, where clinical criteria help guide testing decisions.
Management & lifestyle
Management of Beckwith-Wiedemann syndrome centres on monitoring for tumour development and addressing specific clinical features. UK guidelines recommend regular abdominal ultrasound surveillance and blood tests (alpha-fetoprotein measurements) during early childhood to enable early tumour detection. The surveillance protocol typically continues until age eight, when cancer risk declines substantially, though specific recommendations may vary based on individual features and genetic subtype.
Newborns with hypoglycaemia require careful blood sugar monitoring and may need feeding support or, occasionally, medications to maintain appropriate glucose levels. Macroglossia is managed conservatively in many cases, though surgical tongue reduction may be considered if the enlargement significantly impairs feeding, breathing, or development. Children with abdominal wall defects typically undergo surgical repair. Haemihyperplasia may require orthopaedic input if leg-length discrepancy develops. Access to multidisciplinary NHS care, coordinated through paediatric specialists and clinical genetics services, ensures appropriate surveillance and intervention when needed.
UK care pathway
Within the NHS Genomic Medicine Service, Beckwith-Wiedemann syndrome falls under relevant PanelApp gene panels for overgrowth disorders. Referral to clinical genetics typically occurs through paediatricians when characteristic features are recognised, though families may also access genetics services through their GP. Genetic counsellors provide essential support in explaining test results, discussing recurrence risks, and coordinating family testing where appropriate.
Ongoing care involves collaboration between multiple specialties, potentially including paediatric endocrinology, surgery, and oncology depending on individual needs. NHS cancer surveillance programmes for Beckwith-Wiedemann syndrome follow established protocols, with imaging and laboratory monitoring coordinated through specialist paediatric centres. Families receive guidance on recognising symptoms requiring prompt medical attention and maintaining recommended surveillance schedules.
Frequently asked questions
Will my child's overgrowth continue throughout their life?
Growth in Beckwith-Wiedemann syndrome is typically most pronounced during foetal development and early childhood. Most affected children grow at rates closer to the general population as they mature, and final adult height is often within the typical range, though some individuals remain taller than average.
How often does my child need cancer screening?
Current UK recommendations generally suggest abdominal ultrasound scans every three months and blood tests for alpha-fetoprotein every 6-12 weeks until around age eight. Your child's healthcare team will provide a personalised surveillance schedule based on their specific features and genetic test results.
Can surgery help with my child's enlarged tongue?
Tongue reduction surgery is considered for children whose macroglossia significantly affects feeding, breathing, or development. Many children with mild-to-moderate tongue enlargement manage well without surgery. Your paediatric team can discuss whether intervention would be beneficial in your child's specific situation.
If I have another child, what is the chance they will have Beckwith-Wiedemann syndrome?
Recurrence risk depends on the underlying genetic cause in your affected child. For most families where the condition arose from spontaneous epigenetic changes, the recurrence risk is very low (typically 1% or less). If a CDKN1C variant is identified, risks may be higher. Genetic counselling can provide personalised risk assessment for your family.
What should I watch for that might indicate a tumour?
Regular surveillance scans are designed to detect tumours before symptoms appear. However, contact your healthcare team promptly if you notice an abdominal mass, blood in the urine, persistent abdominal pain, or any other concerning symptoms between scheduled appointments.
References
- Daley SF, Mendez MD. Beckwith-Wiedemann Syndrome. 2024. PMID: 32644419
- Mishra D, Chakole V. Beckwith-Wiedemann syndrome. The Pan African medical journal. 2023. PMID: 37426460
- Choufani S, Shuman C, Weksberg R. Beckwith-Wiedemann syndrome. American journal of medical genetics. Part C, Seminars in medical genetics. 2010. PMID: 20803657
- Weksberg R, Shuman C, Beckwith JB. Beckwith-Wiedemann syndrome. European journal of human genetics : EJHG. 2010. PMID: 19550435
- Wang KH, Kupa J, Duffy KA. Diagnosis and Management of Beckwith-Wiedemann Syndrome. Frontiers in pediatrics. 2019. PMID: 32039119
- Mussa A, Kalish JM. Introduction to the Beckwith-Wiedemann Syndrome and Cancer Special Issue. Cancers. 2023. PMID: 37894306
- Munns CF, Batch JA. Hyperinsulinism and Beckwith-Wiedemann syndrome. Archives of disease in childhood. Fetal and neonatal edition. 2001. PMID: 11124932
- Schendel SA. Beckwith-Wiedemann syndrome. International journal of oral and maxillofacial surgery. 2019. PMID: 31230770